1800-272-662
Shopping Cart 0
countryflagAU
Login

Adalta Ltd

Healthcare AU 1AD

0.004AUD
-(-%)

Last update at 2026-03-13T04:45:00Z

Day Range

0.0030.004
LowHigh

52 Week Range

0.00170.01
LowHigh

Fundamentals

  • Previous Close 0.004
  • Market Cap10.20M
  • Volume11308123
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.16186M
  • Revenue TTM0.61M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.39M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.50227M -7.11907M -4.85119M -6.06102M -5.62835M
Minority interest - - - - -
Net income -4.50227M -5.38127M -4.85119M -6.06102M -5.62835M
Selling general administrative 2.56M 2.40M 1.73M 4.33M 2.94M
Selling and marketing expenses 0.08M 0.21M 2.46M - -
Gross profit 0.46M 1.51M 2.99M 0.99M 0.85M
Reconciled depreciation 0.09M 0.06M 0.03M 0.03M 0.03M
Ebit -4.46199M -5.32456M -4.87125M -5.94963M -5.53072M
Ebitda -4.44869M -5.26159M -4.84133M -5.91652M -5.50164M
Depreciation and amortization 0.01M 0.06M 0.03M 0.03M 0.03M
Non operating income net other - - - - -
Operating income -4.37676M -5.26159M -4.87125M -7.76459M -8.55448M
Other operating expenses 5.05M 7.00M 7.31M 8.75M 9.40M
Interest expense 0.06M 0.12M 0.06M 0.11M 0.10M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.05M 0.04M 0.00160M 0.00294M
Net interest income -0.04370M -0.06827M -0.06118M -0.10978M -0.09470M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.73780M - 0.11M 0.10M
Total revenue 0.68M 1.74M 3.47M 2.76M 3.99M
Total operating expenses 4.83M 6.77M 7.78M 8.75M 9.40M
Cost of revenue 0.22M 0.23M 0.47M - 7.01M
Total other income expense net -0.12551M -1.85747M 0.02M 1.70M 2.93M
Discontinued operations - - - - -
Net income from continuing ops -4.50227M -5.38127M -4.85119M -6.06102M -5.62835M
Net income applicable to common shares -4.50227M -5.38127M -4.85119M -6.06102M -5.62835M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 2.14M 5.57M 7.73M 10.65M 9.05M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.34M 0.21M 0.08M 0.08M
Total liab 2.74M 3.54M 5.82M 5.27M 2.66M
Total stockholder equity -0.59824M 2.03M 1.91M 5.38M 6.39M
Deferred long term liab - - - - -
Other current liab - 0.60M 0.67M 0.69M 0.76M
Common stock - 47.40M 42.18M 41.01M 36.23M
Capital stock 49.20M - 42.18M 41.01M 36.23M
Retained earnings -52.02251M -47.52024M -42.13897M -37.28778M -31.22677M
Other liab - - 0.01M 0.02M -
Good will - - - - -
Other assets - 0.00000M - - 0.00000M
Cash 1.31M 3.13M 4.96M 8.74M 5.79M
Cash and equivalents - - - - -
Total current liabilities 1.34M 2.22M 5.81M 3.63M 2.66M
Current deferred revenue - - - - -
Net debt 0.46M -1.51818M -0.94810M -4.73552M -4.10390M
Short term debt - 1.52M 4.01M 2.39M 1.69M
Short long term debt 0.45M - 4.01M 2.39M 1.69M
Short long term debt total - 1.62M 4.01M 4.00M 1.69M
Other stockholder equity - - 1.87M 1.66M 1.38M
Property plant equipment - - 0.04M 0.06M 0.07M
Total current assets 2.14M 5.29M 7.70M 10.58M 8.98M
Long term investments - - - - -
Net tangible assets - - 1.91M 5.38M 6.39M
Short term investments - - - - -
Net receivables - 1.82M 2.70M 1.79M 2.98M
Long term debt 1.32M - 0.00000M 1.61M -
Inventory - - - -0.02131M 0.13M
Accounts payable 0.64M 0.09M 1.12M 0.56M 0.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.15M 1.87M 1.66M 1.38M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M - - -0.07792M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.28M 0.04M 0.06M 0.07M
Capital lease obligations - - - - -
Long term debt total - - 0.00000M 1.61M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments 0.11M -0.06239M -0.00213M -0.02523M -0.00212M
Change to liabilities - - 0.45M 0.23M 0.02M
Total cashflows from investing activities 0.11M -0.06239M -0.00213M -0.02523M -0.00212M
Net borrowings -0.09950M -1.40000M - 2.28M -0.60147M
Total cash from financing activities 1.00M 3.67M 1.27M 7.02M 7.19M
Change to operating activities - - -0.12510M 0.00112M -0.07439M
Net income -4.50227M -5.38127M -4.85119M -6.17240M -5.72599M
Change in cash -1.82786M -1.65606M -3.87104M 2.87M 2.42M
Begin period cash flow 3.13M 4.79M 8.66M 5.79M 3.37M
End period cash flow 1.31M 3.13M 4.79M 8.66M 5.79M
Total cash from operating activities -2.93653M -5.25983M -5.13206M -6.13929M -4.78174M
Issuance of capital stock 1.28M 5.41M 1.28M 5.00M 8.12M
Depreciation - 0.06M 0.03M 0.03M 0.03M
Other cashflows from investing activities 0.11M - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 1.12M 0.74M -0.90578M 1.32M 0.26M
Sale purchase of stock -0.18571M -0.28609M -0.07092M -0.26597M -0.32747M
Other cashflows from financing activities -0.18571M -0.05550M 0.06M 4.00M 1.68M
Change to netincome - - 0.27M 0.39M 0.61M
Capital expenditures 0.00000M 0.06M 0.00213M 0.03M 0.00212M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.32M 0.81M 0.06M 0.00160M 0.00294M
Stock based compensation - 0.28M - - -
Other non cash items -4.25800M -1.03632M - 6.14M 5.60M
Free cash flow -2.93653M -5.32223M -5.13418M -6.16452M -4.78386M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
1AD
Adalta Ltd		 - -% 0.004 - - 16.77 6.39 5.50 -1.0634
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University. The company was incorporated in 2006 and is based in Camberwell, Australia.

Adalta Ltd

697 Burke Road, Camberwell, VIC, Australia, 3124

Key Executives

Name Title Year Born
Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D. CEO, MD & Director NA
Mr. Cameron Jones C.A. Company Sec. NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA
Mr. Cameron Jones C.A. Company Secretary NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA
Mr. Cameron Jones C.A. Company Secretary NA
Mr. Angus Tester Ph.D. Senior Director of Operations NA
Ms. Janette Dixon Head of Business Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.